Acumen Pharmaceuticals Inc

NASDAQ ABOS

Data sourced from iex and EODHD
Download Data

Acumen Pharmaceuticals Inc Working Capital Turnover Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2022: -100.00%

Acumen Pharmaceuticals Inc Working Capital Turnover Ratio 1 year YoY Change (%) is -100.00% for the Trailing 12 Months (TTM) ending September 30, 2022. The working capital turnover ratio measures the efficiency of a company in utilizing its working capital to generate revenue. It is calculated by dividing the revenue by the working capital. This ratio indicates the number of times the company's working capital is converted into revenue during a specific period. A higher working capital turnover ratio suggests more efficient utilization of working capital in revenue generation. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Acumen Pharmaceuticals Inc Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Acumen Pharmaceuticals Inc Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a -100.00% change year over year.
  • Acumen Pharmaceuticals Inc Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.02.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email